Balanced news tone
News Sentiment
4597 sentiment intelligence
Solasia Pharma K.K. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
80/100 classification confidence.
directly relevant articles
high-authority source matches
+0.0% over one week, +13.0% over four weeks, trend inactive, and below fair value.
Isofol reaches new phase Ib/II milestones in Europe – prepares Japanese study with Solasia
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Isofol reaches new phase Ib/II milestones in Europe – prepares Japanese study with Solasia
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Nov 2025 08:00
- Source
- Biostock
Solasia: a journey of developing high-quality pharmaceuticals for cancer patients.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Sep 2023 07:00
- Source
- The Worldfolio
Solasia Announces Launch of Darvias® in Japan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Aug 2022 07:00
- Source
- Business Wire
Solasia Pharma: DARVIAS® Injection 135mg (Generic Name: DARINAPARSIN /Development Code: SP-02) Approved in Japan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Jun 2022 07:00
- Source
- STT Info